Objective
There is a very high need for improving the management of pain. Acute and persistent pain of different origins represent a common medical, social, and economic burden, and its pharmacotherapy is often inadequate. To advance management of pain patients and support decision making in clinical practice, more predictive assessments of treatment success are needed. The development of analgesics is onerous because promising preclinical data often do not translate into the clinic. Improved pharmacodynamic biomarkers could define whether nociceptive signalling is adequately modulated by a new drug, so increasing the chance of successful translation and greatly reducing the risk in initiating clinical development. Further, the pathophysiology of chronic pelvic pain indications is poorly understood and no adequate preclinical models are available, precluding focused preclinical research and leaving affected patients with little hope of relief.
IMI-PainCare aims at making advances in these three pain areas in a complementary manner. Three subprojects will address specific scientific challenges. Subproject PROMPT will identify Patient Reported Outcome Measures as tools to standardise assessments of treatment success of acute and chronic pain in Real World conditions and controlled trials, and so improve its management; subproject BioPain will validate the translatability of pharmacodynamic biomarkers and PK-PD modelling in pain pathways of healthy subjects and preclinical species, thereby offering tools to improve drug development; subprojectTRiPP will identify biomarkers and novel therapeutic pathways of clinical phenotypes of patients with chronic pelvic pain, which after back-translation, can improve how preclinical models reflecting human diseases.
The goal of IMI-PainCare is to improve the care of patients with acute or chronic pain by providing a toolbox to streamline the development process for novel analgesic drugs and to improve treatment quality in clinical practice.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicinesurgery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicinephysiologypathophysiology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
69117 Heidelberg
Germany
See on map
Participants (40)
EH8 9LE Edinburgh
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
9220 Aalborg
See on map
8000 Aarhus C
See on map
02115 Boston
See on map
24118 Kiel
See on map
12277 BERLIN
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1050 Bruxelles / Brussel
See on map
N1 3JS London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1000 Bruxelles / Brussel
See on map
1203 Geneve
See on map
75012 Paris
See on map
00029 Helsinki
See on map
4200 135 Porto
See on map
46010 Valencia
See on map
75654 Paris
See on map
1411 HW Naarden
See on map
WC2R 2LS London
See on map
69123 Heidelberg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
48824 East Lansing, Michigan
See on map
Participation ended
08028 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
BH17 9AT Poole
See on map
4785 509 Trofa
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
E1 4NS London
See on map
3400 Hillerod
See on map
00185 Roma
See on map
Participation ended
T12 YN60 Cork
See on map
1200 Bruxelles / Brussel
See on map
EH8 9YL Edinburgh
See on map
07747 Jena
See on map
1348 Louvain La Neuve
See on map
31080 Pamplona
See on map
OX1 2JD Oxford
See on map
48149 MUENSTER
See on map
52078 Aachen
See on map
51373 Leverkusen
See on map
RG21 4FA Basingstoke
See on map
Participation ended
08038 Barcelona
See on map
4056 Basel
See on map
49131 Petach Tivka
See on map
91058 Evry
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.